SIRT1 and neoplasm: We also found that Sirt1 K/O in LSL-KrasG12D/+ mice treated with cisplatin or erlotinib resulted in a significantly lower tumor burden than that in KRASG12D/+;Sirt1+/+ mice, mice in each single drug treatment group, and KrasG12D/+;Sirt1co/co mice, as determined by H&E staining and determination of the tumor number in the lung region (Fig. 7D, E).